Effect of a new oral contraceptive on metabolism and the cardiovascular system
The purpose of the study is to assess the impact of drospirenone-containing contraceptives on body weight and blood pressure. Material and methods. The study included 45 women (mean age 26,4 ± 1,32 years). All patients received low-dose combined oral contraceptive (COC) containing 30 mcg Ethinyl Est...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2015-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/465 |
| Summary: | The purpose of the study is to assess the impact of drospirenone-containing contraceptives on body weight and blood pressure. Material and methods. The study included 45 women (mean age 26,4 ± 1,32 years). All patients received low-dose combined oral contraceptive (COC) containing 30 mcg Ethinyl Estradiol (EE), 3 mg Drospirenone and 451 mg L-Methylfolate Calcium (Metafolin®) for conraceptive purposes. The contraceptive effect was evaluated by the number of pregnancies in patients receiving COC; side effects were assessed by the renin-aldosterone system function (blood pressure), body weight changes, glucose tolerance (blood glucose and glycated hemoglobin tests) and lipid profile. Study results. The effectiveness of birth control was 100%, without any significant side effects. Conclusion. Low-dose medication Yarina® Plus containing 30 mg micronized EE as betadex clathrate, 3 mg micronized Drospirenone and 451 mg L-Methylfolate Calcium (Metafolin®), in 21/7 regimen, has a high contraceptive efficacy, reduces blood pressure within reference values, regulates body weight and maintains normal levels of lipid and carbohydrate metabolism. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |